Palleon Pharmaceuticals Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
30
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$100M
- Investors
-
8
Palleon Pharmaceuticals General Information
Description
Developer of therapeutics designed to offer glycol-immune checkpoint inhibitors to treat cancer. The company's therapeutics are integrated through insights into the fields of glycoscience and human immunology to create a novel approach to treating cancer by targeting multiple immune cell types, enabling physicians with a wider range of rational combination therapies to treat cancer and tackle resistance to first-generation immuno-oncology agents.
Contact Information
Website
www.palleonpharma.comCorporate Office
- 266 Second Avenue
- Waltham, MA 02451
- United States
Corporate Office
- 266 Second Avenue
- Waltham, MA 02451
- United States
Palleon Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 16-Sep-2020 | $100M | Completed | Clinical Trials - Phase 2 | ||
| 2. Early Stage VC (Series A) | 04-Oct-2017 | Completed | Clinical Trials - Phase 2 | |||
| 1. Accelerator/Incubator | Completed | Clinical Trials - Phase 2 |
Palleon Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Palleon Pharmaceuticals Comparisons
Industry
Financing
Details
Palleon Pharmaceuticals Competitors (13)
One of Palleon Pharmaceuticals’s 13 competitors is NexImmune, a Formerly VC-backed company based in Gaithersburg, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Lycia Therapeutics | Venture Capital-Backed | South San Francisco, CA | ||||
| Pyxis Oncology | Formerly VC-backed | Boston, MA | ||||
| IFM Therapeutics | Venture Capital-Backed | Boston, MA | ||||
| Glycotope | Formerly VC-backed | Berlin, Germany |
Palleon Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Palleon Pharmaceuticals Patents
Palleon Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022257052-A1 | Anti-inflammatory siglec proteins and methods of making and using same | Pending | 16-Apr-2021 | ||
| CA-3215280-A1 | Anti-inflammatory siglec proteins and methods of making and using same | Pending | 16-Apr-2021 | ||
| EP-4323378-A2 | Anti-inflammatory siglec proteins and methods of making and using same | Pending | 16-Apr-2021 | ||
| EP-4323378-A4 | Anti-inflammatory siglec proteins and methods of making and using same | Pending | 16-Apr-2021 | ||
| US-20240156979-A1 | Anti-inflammatory siglec proteins and methods of making and using same | Pending | 16-Apr-2021 | A61K47/6811 |
Palleon Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Palleon Pharmaceuticals Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Citadel Enterprise Americas | Hedge Fund | Minority | ||
| Matrix Capital Management | Hedge Fund | Minority | ||
| Surveyor Capital | Hedge Fund | Minority | ||
| AbbVie Ventures | Corporate Venture Capital | Minority | ||
| Pfizer Ventures | Corporate Venture Capital | Minority |
Palleon Pharmaceuticals FAQs
-
When was Palleon Pharmaceuticals founded?
Palleon Pharmaceuticals was founded in 2015.
-
Where is Palleon Pharmaceuticals headquartered?
Palleon Pharmaceuticals is headquartered in Waltham, MA.
-
What is the size of Palleon Pharmaceuticals?
Palleon Pharmaceuticals has 30 total employees.
-
What industry is Palleon Pharmaceuticals in?
Palleon Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Palleon Pharmaceuticals a private or public company?
Palleon Pharmaceuticals is a Private company.
-
What is the current valuation of Palleon Pharmaceuticals?
The current valuation of Palleon Pharmaceuticals is .
-
What is Palleon Pharmaceuticals’s current revenue?
The current revenue for Palleon Pharmaceuticals is .
-
How much funding has Palleon Pharmaceuticals raised over time?
Palleon Pharmaceuticals has raised $148M.
-
Who are Palleon Pharmaceuticals’s investors?
Citadel Enterprise Americas, Matrix Capital Management, Surveyor Capital, AbbVie Ventures, and Pfizer Ventures are 5 of 8 investors who have invested in Palleon Pharmaceuticals.
-
Who are Palleon Pharmaceuticals’s competitors?
NexImmune, Lycia Therapeutics, Pyxis Oncology, IFM Therapeutics, and Glycotope are some of the 13 competitors of Palleon Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
